more news flow expected this year
The adoption of its GI endomicroscopy technology could also trigger an estimated additional
$9.5 billion in overall healthcare benefits in the US, according to research Optiscan commissioned last year from US-based consultants Latham Biopharm Group.
The information collected from the Gen2 trials will allow Optiscan’s engineers - under professor Keisslich’s guidance - to develop a third-generation (Gen3) flexible endomicroscope. Optiscan expects Gen3 to be ready in the coming year and will use it in any subsequent clinical trials.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $91.88M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.5¢ | $4.037K | 36.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 44761 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 69528 | 3 |
View Market Depth
| Last trade - 12.06pm 25/07/2025 (20 minute delay) ? |
| OIL (ASX) Chart |